Investors Urged to Join Securities Fraud Investigation of Allarity Therapeutics, Inc. by Schall Law Firm

Investigation of Allarity Therapeutics, Inc.

The Schall Law Firm, a prominent national litigation firm advocating for shareholder rights, has launched an investigation focusing on Allarity Therapeutics, Inc. This investigation primarily concerns allegations related to securities fraud affecting investors of Allarity, listed on NASDAQ under the ticker ALLR. The inquiry arises from potential violations of federal securities laws that may involve the issuance of misleading statements or incomplete disclosures.

Background of the Investigation

As part of this investigation, significant attention is being paid to a current report filed by Allarity Therapeutics with the SEC on July 22, 2024. In this report, Allarity disclosed that it had received a "Wells Notice" from the SEC, indicating serious concerns regarding its previous disclosures relating to meetings with the U.S. Food and Drug Administration (FDA). Specifically, the notice pertains to the Company's New Drug Application (NDA) for their drug candidate, Dovitinib, also denoted as Dovitinib-DRP.

The specifics outlined in the Wells Notice reveal that the SEC has made a preliminary determination suggesting enforcement action against Allarity. This enforcement could potentially allege violations of the federal securities laws based on the conduct in question. Additionally, it has come to light that several former officers of Allarity have also received similar Wells Notices, raising further questions regarding the management's responsibilities and the integrity of the Company's operations.

What Investors Should Know

Investors who have suffered financial losses due to their holdings in Allarity Therapeutics are particularly encouraged to engage with Schall Law Firm. The firm is poised to represent these investors in seeking accountability and justice following the allegations. Participation in this investigation provides a pathway for affected shareholders to voice their concerns and explore their legal options.

For those interested in participating, Schall Law Firm invites affected shareholders to make contact for a complimentary consultation regarding their individual situations. This outreach is especially pertinent for those holding shares during the specified time when the alleged misstatements and omissions occurred.

How to Reach Out

Investors can contact Brian Schall at the Schall Law Firm via phone at 310-301-3335 or visit the firm's website at www.schallfirm.com for more information. This consultation is offered free of charge and aims to assess each investor's rights and possible claims in light of the circumstances surrounding Allarity Therapeutics.

The firm has a strong track record representing investors against corporate misdeeds and is recognized for its commitment to shareholder rights. The ongoing investigation highlights the importance of transparency and honesty in corporate communications, particularly for publicly traded companies like Allarity.

Conclusion

In conclusion, the investigation into Allarity Therapeutics, Inc. underscores the critical nature of corporate responsibility and the ethical obligations of executives to their shareholders. As the situation continues to develop, affected investors are urged to stay informed and utilize available legal resources to safeguard their interests. The Schall Law Firm stands ready to assist in navigating these complexities as it works to uphold investor rights in the face of alleged misconduct by publicly-traded firms.